All In Biotech

Drug Trial Radar · NCT01072877

Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Polidocanol Injectable Foam 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

Last checked: Nov 20, 2026Latest source record: Apr 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

279

Actual

Start

Dec 2010

Primary completion

Dec 2011

Study completion Nov 2012

Sponsor

Lead sponsor
Boston Scientific CorporationIndustry
Sponsor type
Industry
First posted
Feb 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of three different concentrations of an investigational drug, polidocanol injectable foam compared to vehicle (inactive solution) in treating the symptoms and appearance of varicose veins.

Conditions

  • Varicose Veins

Interventions

  • Polidocanol injectable foam (PEM)Drug

    Injection of Polidocanol injectable foam

  • Placebo VehicleDrug

    Placebo vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score)Time frame: Week 8

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Laguna Hills, California

  • Site not named

    San Diego, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Aventura, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Oakbrook Terrace, Illinois

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Hartsdale, New York

  • Site not named

    New York, New York

  • Site not named

    North Tonawanda, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Toledo, Ohio

  • Site not named

    Bend, Oregon

  • Site not named

    Clarksville, Tennessee

  • Site not named

    Kirkland, Washington

  • Site not named

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.